Stocks Health care AARD
NASDAQ · Health careAardvark Therapeutics, Inc. (AARD)
It posted a net loss of $69.9M. In fiscal 2025 capital spending exceeded operating cash flow by $54.3M. At June 30, 2026 it held $73.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Aardvark Therapeutics, Inc.
- Net worth
- Aardvark Therapeutics, Inc. has a market value (market cap) of $29.5M at the latest share price, and shareholders' equity of $74.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $57.6M.
- Cash flow
- In fiscal 2025 operations used $54.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aardvark Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Aardvark Therapeutics, Inc. does
Aardvark Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AARD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$57.6M | -$2.93 | -$54.3M |
| 2025 | n/a | -$20.6M | -$5.15 | -$18.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Aardvark Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 23, 2026Other event 8-K
- October 22, 2026Other event 8-K
- October 8, 2026Executive or director change8-KAardvark Therapeutics appointed Dr. David Zhang as an independent Class II director.
- August 17, 2026
- August 11, 2026
- August 11, 2026
- July 10, 2026
- July 10, 2026Proxy statement DEF 14A
- June 29, 2026Preliminary proxy statement PRE 14A
- June 12, 2026
Insider trades
What the people running Aardvark Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $395K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 11, 2026 | Sun NelsonSee Remarks | Soldpre-planned (10b5-1) | 62,000 | $321.2K |
| September 10, 2026 | Sun NelsonSee Remarks | Soldpre-planned (10b5-1) | 14,754 | $73.8K |
| December 11, 2025 | Lee Tien-LiChief Executive Officer, Director, 10% owner | Bought | 7,000 | $101.4K |
| December 11, 2025 | Sun NelsonChief Financial Officer | Bought | 3,000 | $43.2K |
Who owns AARD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Xiangmin Cui13G, passive with 4 related filers | 18.3% | February 24, 2025 |
| Tien-Li Lee13G, passive with 1 related filers | 13.7% | May 15, 2025 |
| Vickers Venture Fund VI Pte. Ltd.13G, passive with 2 related filers | 9.58% | February 24, 2025 |
| Kenneth Griffin13G, passive with 6 related filers | 5.6% | February 24, 2025 |
Largest institutional holders
Insiders
2 insiders reported holding 1,695,572 shares in total, about $2.3M at the last price.
| Holder | Shares |
|---|---|
| Lee Tien-LiChief Executive Officer, Director, 10% owner | 1,551,613 |
| Sun NelsonSee Remarks | 143,959 |
Questions about AARD
What does Aardvark Therapeutics, Inc. do?
Aardvark Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as AARD. Its shares trade on NASDAQ under the ticker AARD.
What is Aardvark Therapeutics, Inc.'s net worth?
Aardvark Therapeutics, Inc. has a market value (market cap) of $29.5M at the latest share price, and shareholders' equity of $74.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aardvark Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $69.9M.
When did Aardvark Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 23, 2026.
When is Aardvark Therapeutics, Inc.'s next earnings report?
Aardvark Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AARD with
Follow AARD
Get an email when Aardvark Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aardvark Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.